References: |
Product Reference:
?The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction: J.P. Incardona, et al.; Development 125, 3553 (1998)
?Pancreas development is promoted by cyclopamine, a hedgehog signaling inhibitor: S.K. Kim & D.A. Melton; PNAS 95, 13036 (1998)
?Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine: J. Taipale, et al; Nature 406, 1005 (2000)
?Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened: J.K. Chen, et al.; Genes Dev. 16, 2743 (2002)
?Hedgehog signalling in colorectal tumour cells: induction of apoptosis with cyclopamine treatment: D. Qualtrough, et al.; Int. J. Cancer 110, 831 (2004)
?The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells: R.J. Levitt, et al.; Cancer Lett. 255, 300 (2007)
?Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma: E.E. Bar, et al.; Stem Cells 25, 2524 (2007)
?The hedgehog inhibitor cyclopamine induces apoptosis in leukemic cells in vitro: J. Warzecha, et al.; Leuk. Lymph. 49, 2383 (2008)
?Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo): X. Zhang, et al.; Breast Cancer Res. Treat. 115, 505 (2009)
?Cyclopamine and hedgehog signaling: chemistry, biology, medical perspectives: P. Heretsch, et al.; Chem. Int. Ed. Engl. 49, 3418 (2010) (Review)
?Targeting the hedgehog pathway: the development of cyclopamine and the development of anti-cancer drugs targeting the hedgehog pathway: A. Gould & S. Missailidis; Mini Rev. Med. Chem. 11, 200 (2011) (Review)
? |